^
Association details:
| Biomarker: | KIT exon 13 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial
Published date:
01/20/2022
Excerpt:
In archived tumor samples, 67% (68/102) had a KIT mutation; 61% (62/102) had primary KIT mutations (exons 9 and 11) and 12% (12/102) had secondary mutations (exons 13, 14, 17, and 18)….Regorafenib showed PFS benefit across all primary and secondary KIT mutational subgroups examined....These data support the results of the GRID trial, and suggest that patients may benefit from regorafenib in the presence of KIT mutations...
DOI:
https://doi.org/10.1007/s10120-021-01274-6
Source:
Title:
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
Excerpt:
...Screening of mutations done in exon 11, 9, 13 and 17 in KIT gene and in 12 and 18 exons of PDGFR gene 5....
Trial ID:
Source:
Title:
Clinical trial of regorafenib as the treatment for patients with KIT/PDGFR wild type GIST that have not received any treatment for the metastatic disease Ensayo clínico de regorafenib como tratamiento para pacientes con GIST KIT/PDGFR wild type que no han recibido tratamiento previo para la enfermedad metastásica
Excerpt:
...Paraffin-embedded tumor block must be provided by all subjects during screening period.- Screening of mutations done in exon 11, 9, 13 and 17 in KIT gene and in 12 and 18 exons of PDGFR gene - Subjects must have at least one measurable lesion according to RECIST v1.1 criteria. ...
Trial ID:
